# Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

> **NCT05140512** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** LY01005
- **DRUG:** ZOLADEX® 3.6 mg

## Key facts

- **NCT ID:** NCT05140512
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2021-09-15
- **Final completion:** 2021-11-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140512, "Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05140512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*